Fractures due to osteoporosis are a major health concern, affecting millions of Americans each year. While bone density scans help identify at-risk patients, they don’t provide a complete picture of bone quality or strength, leaving clinicians with limited tools to predict fracture risk accurately.
Active Life Scientific’s OsteoProbe, recently cleared by the FDA, addresses this gap. It is the first device approved to measure the Bone Material Strength index (BMSi), offering a minimally invasive way to assess bone tissue quality.
OsteoProbe works by gently probing the surface of the bone at key sites such as the wrist, hip, and spine—areas most vulnerable to fractures. The device measures how the bone material responds to a controlled mechanical impact, producing a BMSi score that correlates strongly with overall bone strength.
This method provides actionable information that complements traditional bone density scans, giving clinicians a more complete understanding of fracture risk.
An NIH-funded study confirmed that OsteoProbe measurements closely match ex vivo tests of whole bone strength across multiple skeletal sites, supporting its reliability.
Alexander Proctor, Active Life’s founder, highlights its clinical value: “OsteoProbe allows point-of-care assessment of bone strength, helping clinicians identify at-risk patients earlier, tailor treatments, and reduce fractures.”
With osteoporosis affecting over ten million Americans and millions more at risk, OsteoProbe represents a major step forward in proactive, personalized bone health care.
Artículo escrito por el equipo de redacción de Ross Law
30/09/2025
Source:
Medical Device Network